News Story: Full Text
Sponsored By
Cleveland Clinic Brain Tumor and Neuro-Oncology Center
Please Click On The Above Banner For More Details

 

 


Click HERE to return to brain tumor news headlines
Braintumor Website

 

Six year survival after prolonged temozolomide treatment in a 30-year-old patient with glioblastoma.


Posted on: 11/12/2009

 

  Acta Neurol Belg. 2009 Sep;109(3):238-42.

Six year survival after prolonged temozolomide treatment in a 30-year-old patient with glioblastoma.

Poelen J, Prick MJ, Jeuken JW, Wesseling P, Bernsen HJ.

Dept. of Neurology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands. jpoelen@hotmail.com

Glioblastoma (GBM) is the most malignant primary brain tumour in adults. Since 2005 surgery followed by radiotherapy with concomitant Temozolomide (TMZ) is the standard care for patients with a GBM. Despite these improved treatment strategies, survival of GBM-patients remains poor; and there are very few patients who survive for a long time. Also there is no standard therapeutic strategy after six cycles of TMZ, and further treatment is at the physician's discretion. We report a case of a young patient with a glioblastoma who, not only showed dramatic clinical and radiological improvement after TMZ treatment but who now also (under continued TMZ therapy) survives over 6 years, with complete remission clinically and radiologically. Up till now there are no studies describing TMZ treatment in GBM patients for as long as 6 years.

  PMID: 19902821 [PubMed - in process]
  Related articles


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740